ASweetLife Team, Author at ASweetLife

The Holiday Season’s Must-Read: Diabetes Diagnosis Stories

Every person with diabetes has a unique diagnosis story. Whether or not their diagnosis story is one they share with the world-at-large, it’s a defining one, a life-changing event. What not everyone knows, though, is that it doesn’t have to be a negative one.

EU Approves Forxiga for Treatment of Type 2 Diabetes Patients

The European Commission has approved Bristol-Myers Squibb and AstraZeneca's new type 2 diabetes therapy, Forxiga (dapagliflozin), for use in the European Union (EU). Forxiga is a selective and reversible inhibitor of sodium-glucose cotransporter 2 (SGLT2) that works independently of insulin to help remove excess glucose from the body

T1D Exchange and Sanofi Team Up For Study Of Diabetes Care in Young Patients

T1D Exchange, a non-profit organization focused on type 1 diabetes, and Sanofi have joined forces in the TEENs registry study, a study aimed at providing a better understanding of how children, adolescents and young adults are currently living with type 1 diabetes and to deliver recommendations for better disease management and patients outcomes.

Degludec, Novo Nordisk’s New Insulin, On Its Way To FDA Approval

The Endocrinologic and Metabolic Drugs Advisory Committee of the United States Food and Drug Administration (FDA) completed its meeting regarding the New Drug Applications (NDA) for Novo Nordisk's insulin degludec (to be marketed under the name Tresiba) and insulin degludec/insulin aspart.

Hurricane Relief for JDRF

If you visit the JDRF website, a pop-up appears that details the affects of Hurricane Sandy on their employees and their New York office, which remains closed. It's always a great idea to donate to JDRF, and now is an especially good time. JDRF's statement is below.

‘Diabesties’, CDN’s New App, available in Apple App Store

The College Diabetes Network (CDN) in partnership with Ayogo is pleased to announce the release of its Diabesties app for iPhone. "Diabesties" harnesses the power of social accountability and engagement to benefit people living with diabetes.

No Sugar Added Baked Apples Recipe

Baked apples are a fall favorite, and even if you follow a low-carb diet you get to indulge at least once a season, right? There is no sugar added…

Seven Halloween Treats for Kids that Aren’t Candy

One Halloween when I was eight-years-old and my brother was five, we had the world’s most successful trick-or-treating. We got such an…

EU Panel Backs Novo Nordisk’s Tresiba

The Committee for Medicinal Products for Human Use (CHMP) under the European Medicines Agency (EMA) adopted positive opinions, recommending marketing authorizations, for Novo Nordisk's new insulin Tresiba and insulin Ryzodeg for the treatment of diabetes mellitus in adults. Tresiba , the intended brand name for insulin degludec, is a new generation of once-daily basal insulin. In "treat-to-target? studies supporting the new drug application, where Tresiba was compared to insulin glargine,

New Dexcom G4 PLATINUM Approved by FDA

The U.S. FDA has approved Dexcom's new continuous glucose monitoring system, the Dexcom G4™ PLATINUM. According to clinical trials the new Dexcom G4 PLATINUM has much improved accuracy with up to approximately 19 percent improvement in overall accuracy for the Dexcom G4 PLATINUM compared to the Seven Plus, and approximately a 30 percent improvement in accuracy in the hypoglycemia range. The overall accuracy and ease of use for the Dexcom G4 PLATINUM sets a new standard for commercially available CGMs, making the Dexcom G4 PLATINUM the most-advanced CGM system available.